Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function
Early changes associated with the development of smoking-induced diseases, e.g., COPD and lung cancer (the two commonest causes of death in U.S.) are often characterized by abnormal airway epithelial differentiation. Airway basal cells (BC) are stem/progenitor cells necessary for generation of differentiated airway epithelium. Based on our preliminary observations that epidermal growth factor receptor, known to regulate airway epithelial differentiation, is enriched in BC and its ligand EGF is induced by smoking, we hypothesized that smoking-induced EGF alters the ability of BC to form normally differentiated airway epithelium. To test this, airway BC will be purified using a cell-culture method established in our laboratory and responses to EGF will be analyzed using genome-wide microarrays and an in vitro air-liquid interface model of airway epithelial differentiation.
Airway epithelium is composed of 4 major cell types, including ciliated cells, secretory
cells, undifferentiated columnar cells, and basal cells (BC). The earliest changes associated
with the development of smoking-induced lung diseases, such as chronic obstructive pulmonary
disease (COPD) and lung cancer, occur in the airway epithelium, including BC hyperplasia,
squamous metaplasia, mucous cell hyperplasia and metaplasia, impaired ciliated cell structure
and function, loss of Clara cells, and increased epithelial permeability due to impaired
junctional barrier. We hypothesize that fundamental to these changes are smoking-induced
derangements of BC, the stem/progenitor cell population that can self-renew and differentiate
into ciliated and secretory cells. Using technologies established in our laboratory to
culture pure population of BC from the human airway epithelium, to induce differentiation of
these BC in air-liquid interface, and to assess the transcriptome of purified BC compared to
that of the complete differentiated airway epithelium, our preliminary data indicates that:
(1) airway BC exhibit a distinct gene expression signature relevant to stem/progenitor cell
function, including high expression of the epidermal growth factor receptor (EGFR); (2)
airway BC from healthy smokers have a different gene expression pattern compared to
nonsmokers, with enrichment of functional categories related to cell cycle and proliferation
and down-regulation of differentiation-associated genes; and (3) constitutive EGF expression
in BC and differentiated cells is barely detectable, but smoking selectively up-regulates EGF
expression in differentiated cells of the airway epithelium in vivo. Based on these data and
on the knowledge that EGFR signaling plays a central role in the regulation of cell
proliferation and differentiation in the airway epithelium, the central concept of this
proposal is that smoking-induced expression by differentiated cells activates BC via EGFR
altering the molecular phenotype of airway BC and impairing their ability to generate normal
differentiated airway epithelium. To assess this concept, the following aims will be
addressed:
Aim 1. To determine whether stimulation of airway BC from healthy nonsmokers with EGF induces
genes and pathways related to smoking-associated phenotypes, e.g. BC hyperplasia, squamous
metaplasia, mucous metaplasia, abnormal cilia, decreased Clara cell number and compromised
junctional integrity.
Aim 2. To test the hypothesis that stimulation of airway BC from healthy nonsmokers with EGF
alters BC differentiation in air-liquid interface culture, with generation of
smoking-associated phenotypes (see Aim 1).
Aim 3. To test the hypothesis that upon apical exposure to cigarette smoke extract,
differentiated airway epithelial cells derived from BC of healthy nonsmokers release
increased amounts of EGF into the apical supernatant, which will alter the ability of BC of
healthy nonsmokers to generate normal differentiated airway epithelium, and that blocking EGF
in this supernatant will abolish this effect.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|